Ranolazine: A Contemporary Review.
作者信息
Rayner-Hartley Erin, Sedlak Tara
机构信息
University of British Columbia, Vancouver, British Columbia, Canada.
University of British Columbia, Vancouver, British Columbia, Canada
出版信息
J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
Abstract
摘要
相似文献
1
Ranolazine: A Contemporary Review.雷诺嗪：当代综述。
J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
2
New Anti-Anginal Drugs: Ranolazine.新型抗心绞痛药物：雷诺嗪。
Cardiovasc Hematol Agents Med Chem. 2015;13(1):14-20. doi: 10.2174/1871525713666141219112841.
3
Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.慢性稳定性心绞痛的药物治疗：聚焦于雷诺嗪
Cardiovasc Drugs Ther. 2016 Aug;30(4):393-398. doi: 10.1007/s10557-016-6674-1.
4
Pharmacologic management of chronic stable angina.慢性稳定型心绞痛的药物治疗
JAAPA. 2015 Jun;28(6). doi: 10.1097/01.JAA.0000465223.98395.45.
5
Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.从英国视角看雷诺嗪治疗慢性稳定性心绞痛的成本效益分析。
BMJ Open. 2015 Nov 6;5(11):e008861. doi: 10.1136/bmjopen-2015-008861.
6
Treatment of Angina: Where Are We?心绞痛的治疗：我们目前处于什么阶段？
Cardiology. 2018;140(1):52-67. doi: 10.1159/000487936. Epub 2018 Jun 6.
7
New oral nitric oxide-dependent medications for patients with coronary artery disease who have persistent angina pectoris.用于患有持续性心绞痛的冠心病患者的新型口服一氧化氮依赖性药物。
Coron Artery Dis. 2015 Dec;26(8):639-41. doi: 10.1097/MCA.0000000000000287.
8
Extended-release ranolazine: critical evaluation of its use in stable angina.缓释雷诺嗪：对其在稳定型心绞痛中应用的批判性评价。
Vasc Health Risk Manag. 2011;7:535-9. doi: 10.2147/VHRM.S15560. Epub 2011 Aug 25.
9
Update on evidence for treatment with ranolazine in stable angina.关于雷诺嗪治疗稳定性心绞痛的证据更新。
Swiss Med Wkly. 2013 Oct 25;143:w13874. doi: 10.4414/smw.2013.13874. eCollection 2013.
10
Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.在患有冠状动脉微血管功能障碍的受试者中，心肌组织变形减少，但雷诺嗪治疗未能使其恢复。
Clin Cardiol. 2017 May;40(5):300-306. doi: 10.1002/clc.22660. Epub 2016 Dec 22.
引用本文的文献
1
Developing a novel aging assessment model to uncover heterogeneity in organ aging and screening of aging-related drugs.开发一种新型衰老评估模型，以揭示器官衰老的异质性并筛选与衰老相关的药物。
Genome Med. 2025 Jul 24;17(1):83. doi: 10.1186/s13073-025-01501-0.
2
Ranolazine as a therapeutic agent for diabetic cardiomyopathy: reducing endoplasmic reticulum stress and inflammation in type 2 diabetic rat model.雷诺嗪作为治疗糖尿病性心肌病的药物：在2型糖尿病大鼠模型中减轻内质网应激和炎症反应
BMC Pharmacol Toxicol. 2025 May 27;26(1):111. doi: 10.1186/s40360-025-00945-9.
3
Unveiling the Longitudinal Journey: 3-Year Follow-up of Women with MINOCA and INOCA in a Specialized Heart Centre.揭示纵向历程：在一家专业心脏中心对患有心肌梗死型非阻塞性冠心病（MINOCA）和缺血性非阻塞性冠心病（INOCA）的女性进行的3年随访
CJC Open. 2024 Sep 3;6(12):1462-1475. doi: 10.1016/j.cjco.2024.08.013. eCollection 2024 Dec.
4
Ranolazine Unveiled: Rediscovering an Old Solution in a New Light.雷诺嗪揭秘：以新视角重新发现一种旧疗法。
J Clin Med. 2024 Aug 23;13(17):4985. doi: 10.3390/jcm13174985.
5
Structural basis for inhibition of the cardiac sodium channel by the atypical antiarrhythmic drug ranolazine.非典型抗心律失常药物雷诺嗪对心脏钠通道抑制作用的结构基础。
Nat Cardiovasc Res. 2023 Jun;2(6):587-594. doi: 10.1038/s44161-023-00271-5. Epub 2023 May 4.
6
Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers.神经元中的持续钠电流：潜在机制和药理学阻断剂。
Pflugers Arch. 2024 Oct;476(10):1445-1473. doi: 10.1007/s00424-024-02980-7. Epub 2024 Jul 5.
7
Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials.雷诺嗪改善非阻塞性冠状动脉疾病患者冠状动脉微血管功能：一项随机对照试验的系统评价和荟萃分析以及试验序贯分析
Quant Imaging Med Surg. 2024 Feb 1;14(2):1451-1465. doi: 10.21037/qims-23-1029. Epub 2024 Jan 9.
8
Amorphous Solid Forms of Ranolazine and Tryptophan and Their Relaxation to Metastable Polymorphs.雷诺嗪和色氨酸的无定形固体形式及其向亚稳多晶型物的弛豫
Cryst Growth Des. 2023 Aug 18;23(9):6679-6691. doi: 10.1021/acs.cgd.3c00565. eCollection 2023 Sep 6.
9
Conductance Changes of Na Channels during the Late Na Current Flowing under Action Potential Voltage Clamp Conditions in Canine, Rabbit, and Guinea Pig Ventricular Myocytes.犬、兔和豚鼠心室肌细胞在动作电位电压钳制条件下晚期钠电流流动期间钠通道的电导变化
Pharmaceuticals (Basel). 2023 Apr 7;16(4):560. doi: 10.3390/ph16040560.
10
The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净通过增加心肌细胞内三磷酸腺苷生成改善糖尿病小鼠心脏能量代谢
Commun Biol. 2023 Mar 17;6(1):278. doi: 10.1038/s42003-023-04663-y.
本文引用的文献
1
A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.一项关于晚期钠电流抑制药物（雷诺嗪）治疗冠状动脉微血管功能障碍（CMD）的随机、安慰剂对照试验：对心绞痛和心肌灌注储备的影响。
Eur Heart J. 2016 May 14;37(19):1504-13. doi: 10.1093/eurheartj/ehv647. Epub 2015 Nov 27.
2
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.经皮冠状动脉介入治疗（PCI）后不完全血运重建患者应用雷诺嗪（RIVER-PCI）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22.
3
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.HARMONY试验：联合使用雷诺嗪和决奈达隆治疗阵发性心房颤动：机制与治疗协同作用
Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1048-56. doi: 10.1161/CIRCEP.115.002856. Epub 2015 Jul 30.
4
Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.雷诺嗪对伴或不伴急性冠状动脉综合征经皮冠状动脉介入治疗的慢性心绞痛患者的影响：来自MERLIN-TIMI 36试验的观察结果
Clin Cardiol. 2015 Aug;38(8):469-75. doi: 10.1002/clc.22425. Epub 2015 Jun 8.
5
Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.雷诺嗪单药治疗对2型糖尿病患者血糖控制的影响。
Diabetes Care. 2015 Jul;38(7):1189-96. doi: 10.2337/dc14-2629. Epub 2015 Jun 6.
6
Antiarrhythmic properties of ranolazine: A review of the current evidence.雷诺嗪的抗心律失常特性：当前证据综述
Int J Cardiol. 2015;187:66-74. doi: 10.1016/j.ijcard.2015.03.324. Epub 2015 Mar 21.
7
Coronary microvascular dysfunction, microvascular angina, and treatment strategies.冠状动脉微血管功能障碍、微血管性心绞痛及治疗策略
JACC Cardiovasc Imaging. 2015 Feb;8(2):210-20. doi: 10.1016/j.jcmg.2014.12.008.
8
Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.雷诺嗪治疗心房颤动：剂量范围研究RAFFAELLO（电复律后心房颤动中的雷诺嗪）的结果
Heart Rhythm. 2015 May;12(5):872-8. doi: 10.1016/j.hrthm.2015.01.021. Epub 2015 Jan 17.
9
Ranolazine: Drug overview and possible role in primary microvascular angina management.雷诺嗪：药物概述及其在原发性微血管性心绞痛治疗中的可能作用。
Int J Cardiol. 2015 Feb 15;181:376-81. doi: 10.1016/j.ijcard.2014.12.055. Epub 2014 Dec 23.
10
Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.雷诺嗪短期治疗可预防冠状动脉搭桥术和瓣膜手术后的房颤。
Clin Res Cardiol. 2015 May;104(5):410-7. doi: 10.1007/s00392-014-0796-x. Epub 2014 Nov 22.
Zotero 插件